New biologic therapeutics for ulcerative colitis and Crohn's disease.
about
Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targetsInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsDifferential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectivesExperiences of complementary and alternative medicine in patients with inflammatory bowel disease - a qualitative study.Inflammatory bowel disease therapies discontinued between 2009 and 2014.Management of arthropathy in inflammatory bowel diseases.Consistent defined threshold and equity in health.Corticosteroid therapy in ulcerative colitis: Clinical response and predictors.T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitisNovel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.The alternate effects of anti-TNFα therapeutics and their role in mycobacterial granulomatous infection in Crohn's disease.Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art.Pharmacogenetic biomarkers of response in Crohn's disease.Biological drugs for inducing remission in patients with Crohn's disease: determining statistical equivalence according to evidence-based methodsBeneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis.Novel benzoxazole derivatives DCPAB and HPAB attenuate Th1 cell-mediated inflammation through T-bet suppression.γδ T cells provide the early source of IFN-γ to aggravate lesions in spinal cord injury.Unilateral and irreversible optic neuropathy associated to infliximab treatment: 3-year follow-up.Psoriasis and inflammatory bowel disease: links and risks.
P2860
Q26752806-7432C2CE-1AC1-42B4-989B-BB637C43C9CDQ26785537-EF2438B7-0DCA-4132-BFE8-D9F2A46066DCQ28085134-B844ECE7-0D97-4AAD-9A51-19DF4CBAB8B7Q34410515-603FF377-96D1-4733-BB88-982423C45D20Q34471161-5F26FFF3-12A7-4810-A965-34AD88DE1A6BQ35091366-8F083161-5640-4FE5-9905-A5167907D5FCQ35101224-181A6A16-F756-40A9-9B9C-142ED7056330Q35169366-89DA7D0A-6B99-45B7-A89D-D34F91E8EFFBQ36093770-F3DCFAB6-12A1-4562-8FB6-19C1777DFC26Q38253844-099577A2-4FCF-4982-A894-77E528BA6728Q38265958-303E9941-BD6E-430B-90A2-6114D4E09307Q38293774-3AD37799-4C42-405A-86B6-BBD6CA8496ACQ38365426-507908E7-24DA-40FA-9CF3-1EE09C9A3A2FQ38460376-A6473ECE-1E5B-4E51-9C50-660E3DEF010AQ38686563-52051036-DA57-4369-A297-0D88F7B669EAQ38968166-0A02BBD7-C1F2-4BFC-8340-6DA9523B1DC8Q39385446-0CEA190C-B120-47FD-8B4D-775481319EA8Q40429147-EBBBF0DE-E134-4CC6-AD02-FA9C1A4A58C8Q41790367-FEE74B39-2A8E-4B50-B3A5-EB501EE91306Q42323585-AF473CEA-790B-4AEF-88E6-E078E4946363Q47215543-EAE095D9-0D6B-4593-84B3-0EDBABD9B525Q47608255-599E646E-EE82-4726-BACA-347EC570C40AQ52859380-82E721F1-8BD5-48FD-A50B-B6D6AD754105
P2860
New biologic therapeutics for ulcerative colitis and Crohn's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New biologic therapeutics for ulcerative colitis and Crohn's disease.
@en
type
label
New biologic therapeutics for ulcerative colitis and Crohn's disease.
@en
prefLabel
New biologic therapeutics for ulcerative colitis and Crohn's disease.
@en
P2860
P1476
New biologic therapeutics for ulcerative colitis and Crohn's disease.
@en
P2093
Shekoufeh Nikfar
Shilan Mozaffari
P2860
P304
P356
10.1517/14712598.2014.885945
P407
P577
2014-02-06T00:00:00Z